Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.
Also called NCT05369975
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 113 participants
- Sponsor
- Hansa Biopharma AB
- Registry
-
NCT05369975 -
2021-002640-70
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Slovenia, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05369975. Non-randomized; no masking; primary purpose treatment. Start 2022-04-19 (actual); primary completion 2026-04-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
- Acronym
- PAES
- Condition
- Kidney Transplantation in Highly Sensitized Patients
- Intervention (Drug)
- Imlifidase
- Intervention (Other)
- Normal Transplantation Routine
- Lead sponsor
- Hansa Biopharma AB
Record details
- Record id
cardio:ct-nct05369975- Content hash
1b3d6b465226546b122bf1c1ff3da1c0b9b555861651e93adb44df16203f7018